Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis due to challenges in early diagnosis, aggressive tumor biology, and limited treatment options. Research has shown a link between gut microbiota dysbiosis and PDAC, suggesting that manipulating the microbiome could aid in screening, diagnosing, and treating the disease. Fecal microbiota transplantation (FMT) shows promise as an adjunct therapy for PDAC by modulating the microbiome. The gut microbiome’s impact on immune regulation, microbiota-derived metabolites, and combining FMT with cancer treatments are areas of active research. However, challenges such as donor screening and standardizing procedures need to be addressed for FMT to reach its full potential in PDAC management.
Source link
Understanding gut microbial imbalance in pancreatic cancer development and treatment
